Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety follow-up study of prior romosozumab treatment in children and adolescents with osteogenesis imperfecta
CTR20263698Phase 3Active
- Sponsor
- Amgen
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of romosozumab in osteogenesis imperfecta (OI), sponsored by Amgen. Started Oct 2026; status: active.
02
Drugs
romosozumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on CTR20263698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263698.